Corticosteroids or Immunosuppressive Therapy Tapering Increases Flares in Stable SLE
Researchers analyzed corticosteroids or immunosuppressive therapy tapering across 14,808 patient-visits among 3002 patients with systemic lupus erythematosus.
Systemic Lupus Erythematosus
Reduction in Swollen, Tender Joints Greater With Litifilimab in Lupus
Most secondary end points did not support the results of the analysis for the primary end point
Dose Range for Iberdomide Studied in Systemic Lupus Erythematosus
For percentage of patients achieving specified reduction in disease activity, iberdomide superior to placebo only at highest dose tested
February 2022 Recap: Drug Pipeline Updates
A review of regulatory and drug development status updates.
Lilly Ends Baricitinib Lupus Program, Provides Update on Atopic Dermatitis sNDA
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.
New Drugs Approved in 2021
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Belimumab Promising in Combination Therapy for Refractory Lupus
Lower serum IgG anti-dsDNA antibody levels seen at 52 weeks with belimumab rather than placebo given after rituximab
Promising Developments That May Improve Lupus Nephritis Management
Recent approval of new drugs for lupus nephritis and promising therapies on the horizon bode well for the care of patients with the kidney disorder.
New Drug Product: Saphnelo
This slideshow shows drug information for Saphnelo. Click here for the complete Saphnelo monograph.
MPR Weekly Dose Podcast Episode 88
The FDA authorizes a postexposure prophylaxis for COVID-19; A new treatment is okay’d for lupus; A higher dose naloxone nasal spray became available; The risk evaluation and mitigation program for Clozapine has had important changes, and finally, Istodax has had an indication withdrawn.
